What is it about?
Cefepime is a widely used antibiotic against Gram-negative bacteria, but many of these germs now produce enzymes (beta-lactamases) that destroy it, or pump it out of the cell. To restore its activity, cefepime is being combined with new 'protector' molecules that block these enzymes: enmetazobactam, taniborbactam, zidebactam and nacubactam. In this review we describe how each combination works, which resistant bacteria it can cover - such as ESBL- and carbapenemase-producing Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii - the results of laboratory and clinical studies, and the pharmacokinetic/pharmacodynamic data that guide correct dosing.
Featured Image
Photo by Fusion Medical Animation on Unsplash
Why is it important?
Multidrug-resistant Gram-negative infections are among the most urgent threats in hospitals, and treatment options are shrinking. Cefepime-based combinations are arriving in clinical practice and differ considerably in spectrum: enmetazobactam mainly restores activity against ESBLs, while taniborbactam and zidebactam also cover some metallo-beta-lactamases. This review gives clinicians and microbiologists a single, practical reference to position these new drugs correctly and use them wisely.
Perspectives
New antibiotics are precious and must be used with judgment. Knowing exactly which resistance mechanisms each cefepime combination can overcome is what allows us to choose the right drug for the right patient and protect these molecules for the future. It was a pleasure to work with a large Italian network of microbiologists, pharmacologists and infectious diseases specialists.
Professor Stefano Di Bella
Universita degli Studi di Trieste
Read the Original
This page is a summary of: Cefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics, Pharmaceuticals, February 2026, MDPI AG,
DOI: 10.3390/ph19020283.
You can read the full text:
Contributors
The following have contributed to this page







